Professional Documents
Culture Documents
No 2 Ranked PharmD program (most recent ranking in US News & World Report) Ranked #2 in NIH Funding, 2010 105 Faculty , 600 PharmD students, 110 Graduate students Over 200,000 sq ft of research/teaching space (3 buildings) equipped with state-of-the art VTC and distance education technology
Academic Programs
PharmD
Medicinal Chemistry & Natural Products Molecular Pharmaceutics
PhD
Pharmacotherapy & Exp. Therapeutics
MS
Pharmaceutical Outcomes & Policy
Synthetic Chemistry Chemical Biology Bio- and Chem-informatics Structural Biology Target Discovery & Validation
Molecular Pharmaceutics
Drug Metabolism & transport Pharmacogenomics PK/PD Modeling & Simulation Clinical Trial Design Clinical Pharmacology
Pharmaceutical Scientists
Discovery to Practice
Discovery Optimization Assessment Outcomes Practice
Molecular Pharmaceutics
Center Capabilities
Assay Development
Protein expression and purification Cell-based or in vitro Multiple platforms and readouts
Compound Screening
Up to 100K compounds possible HTS
Medicinal Chemistry
SAR projects 11 internal chemists + 4 FTEs in China and access to more as needed Compound synthesis
Computational Chemistry
Design of screening sets Virtual screening Structure-based design
Access to novel biological targets discovered by UNC faculty across therapeutics areas - targets validated with small molecules Research focus on innovative targets in chromatin biology & epigentics NCI-designated Comprehensive Chemical Biology Center Leadership with industrial track record of discovery of FDA approved drugs
Features of CICBDD
The focus of the CNDD is to safely and effectively translate new drug and imaging discoveries into clinical trials using nanotechnology with the goal to improve human health.
4 Nanotoxicology
RTP EPA, NIEHS
Federal Agencies (NIH, NSF) State of NC Private sector (VC, Industry) UNC students UNC Academic/Research Units UNC-Chapel Hill
CNDD Stakeholders
Mission: Integrate clinical medicine with cutting-edge systems biology and in silico modeling platforms to make drugs safer and advance drug development.
Drug Discovery
New Molecular Entities
(problems) Stabilize NMEs
Drug Delivery
Facilitate in-vitro screening
Small molecules
Unstable Insoluble Efflux substrates Poor permeability
Increase cell accumulation Range of dosage forms for various routes of administration in preclinical animal efficacy models Advantageously affect ADME and pharmacokinetics Minimize toxicity, Safe (GRAS materials) Cost-effective Scalable under GMP The Essence of Skills in the Center for Nanotechnology in Drug Delivery CMC sections of IND
Nucleic-acid based
Unstable Poor permeability Require intracellular Accumulation
Peptides/proteins
Unstable Poor permeability
and clinicians across allied health schools within UNC with the unifying goal of expediting the path from basic research discoveries to clinical practice.
Lineberger Comprehensive Cancer Center School of Pharmacy Carolina Center for Genome Sciences
Associate Directors: Oncology research Federico Innocenti Pre-clinical PGx Timothy Wiltshire Policy and Ethics Lynn Dressler PGx Applied Technology Karen Weck Clinical PGx James Evans PGx Evidence-based Practices Dan Jonas
IPIT
School of Medicine
Research Areas
Preclinical Pharmacogenomics Policy & Ethics Pharmaco-economics
Partial List of Key Partners: Depts. Chemistry, Physics, Mathematics, & Computer Science Biomanufacturing Research Institute and Technology Enterprise (BRITE) School of Medicine Lineberger Comprehensive Cancer Center (LCCC) UNC Neuroscience Center Carolina Cardiovascular Biology Center North Carolina Center for Nanoscale Materials (NCCNM) Institute for Advanced Materials, Nanoscience and Technology (IAM) UNC Institute for Nanomedicine Carolina Center of Cancer Nanotechnology Excellence (CCCNE) Biomedical Research Imaging Center (BRIC) Bryson Center for Human Genetics North Carolina Translational and Clinical Sciences (TraCS) Institute (via NIH CTSA)
Industry
Research Triangle Park
CICBDD
In-Vivo Screening
- Biological transport; delivery - Pharmacokinetics; ADME Efficacious pre-clinical lead formulations
IPIT
Industry
UNC
Pharma/Biotech companies
Relationships
Area Universities Pharmacy Spinoffs
Qualiber NeuroGate Oriel Therapeutics
Capture Pharmaceuticals
Glycobiology
Functional Proteomics
Natural Products
Pediatric Pharmacotherapy
Michael Cohen-Wolkoweitz
Metabolism/Transport/PK/PD/Pharmacometrics
Mechanisms of Hepatotoxicity
Cardiovascular Pharmacology
Jo Ellen Rodgers, Craig Lee, Herbert, PharmD PharmD, Ph.D. Patterson PharmD
Pharmacogenomics/Cancer Parmacotherapy
Infectious Diseases
Amanda Angela Kashuba, William Zamboni, PharmD PhD, PharmD Corbett, PharmD
Transplant Pharmacotherapy
Outcomes Research
Jaya Rao, MD